Abstract
Polycystic Ovary Syndrome (PCOS) is characterized by chronic anovulation and risk of endometrial hyperplasia. The etonogestrel (ENG) implant is a long-acting option for the prevention of endometrial hyperplasia in adolescents with PCOS. Current studies report adolescent ENG 12-month discontinuation rates at 10%, but there are no data for adolescents with PCOS. We sought to describe why adolescents with PCOS chose ENG, determine the 12-month continuation rate and characterize factors for discontinuation.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call